Press Release | Frontier Medicines

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

August 27, 2025/in 2024, Press Release/by eallison

July 23, 2024

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

August 27, 2025/in 2024, Press Release/by eallison

June 25, 2024

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

August 27, 2025/in 2024, Press Release/by eallison

April 9, 2024

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

August 27, 2025/in 2024, Press Release/by eallison

March 21, 2024

Frontier Medicines to Participate in Upcoming Investor Conferences

August 27, 2025/in 2024, Press Release/by eallison

February 27, 2024

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

August 27, 2025/in 2024, Press Release/by eallison

February 22, 2024

Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference

August 27, 2025/in 2024, Press Release/by eallison

January 3, 2024

Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer

August 27, 2025/in 2023, Press Release/by eallison

May 8, 2023

Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting

August 27, 2025/in 2023, Press Release/by eallison

April 16, 2023

Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting

August 27, 2025/in 2023, Press Release/by eallison

March 14, 2023

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

Frontier Medicines to Participate in Upcoming Investor Conferences

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer

Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting

Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting

Our Locations

South San Francisco Office

Boston Office